Loading
A phase 1/2 trial of Glecirasib, Sitneprotafib in non-small-cell lung cancer and small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation is a phase 1/2 interventional study registered as NCT05288205 by Allist Pharmaceuticals, Inc., with 240 participants planned, started 2022-04-14 and due to reach its primary completion in 2027-03. Interventions recorded: JAB-21822, JAB-3312. Conditions listed: KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sitneprotafib, Shanghai Allist Pharmaceuticals, Glecirasib, KRAS G12C-mutant non-small-cell lung cancer.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS G12C-mutant colorectal cancer, KRAS & RAS inhibitors.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors.
Shares Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer.
Shares Sitneprotafib, Glecirasib, KRAS & RAS inhibitors, Small-molecule kinase inhibitors.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS & RAS inhibitors, Small-molecule kinase inhibitors.
Shares KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/